IOF and IFCC review calls for harmonization of assays for reference bone turnover markers
New review describes the current status of assays for PINP and β-CTX in blood, as well as the plans for and progress towards the achievement of harmonization or standardization of commercial assays for these reference markers
Bone turnover markers (BTMs) in blood and urine are useful tools in monitoring osteoporosis treatment effects and may be useful for improving patient adherence.
In 2011, a Joint Committee on Bone Metabolism of the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) designated Procollagen type I N-propeptide (PINP) and the C-terminal telopeptide of type I collagen (β-CTX) in blood as reference bone turnover markers for bone formation and bone resorption, respectively, in osteoporosis. However, the effective clinical implementation of these recommendations requires the standardization/harmonization of commercial assays [1].
The newly published review ' END
In 2011, a Joint Committee on Bone Metabolism of the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) designated Procollagen type I N-propeptide (PINP) and the C-terminal telopeptide of type I collagen (β-CTX) in blood as reference bone turnover markers for bone formation and bone resorption, respectively, in osteoporosis. However, the effective clinical implementation of these recommendations requires the standardization/harmonization of commercial assays [1].
The newly published review ' END